MedTrace Logo

ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic

NCT04329195 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2021-04-09

No results posted yet for this study

Summary

Since December 2019, a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused an international outbreak of respiratory illness described as COVID-19.

Individuals with a history of cardiovascular disease develop a more severe illness and have higher rates of death.

Because of the potential interaction between RAS blockers and SARS-CoV-2 mechanism of infection, there are ongoing scientific discussions on whether they should be stopped or continued in patients with COVID-19.

It is crucial to determine whether RAS blockers should be discontinued or not in patients with COVID-19.

Conditions

  • History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection

Interventions

DRUG

1: discontinuation of RAS blocker therapy

discontinuation of RAS blocker therapy

DRUG

2: continuation of RAS blocker therapy

continuation of RAS blocker therapy

Sponsors & Collaborators

  • Groupe Hospitalier Pitié-Salpêtrière

    collaborator UNKNOWN

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Gilles MONTALESCOT, MD, PhD · Institut Cardiologie - Pitié Salpêtrière(APHP) / ACTION Study Group / Univ. Paris 6 (UPMC) - INSERM UMRS 1166

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-09
Primary Completion
2020-12-09
Completion
2021-01-09

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04329195 on ClinicalTrials.gov